An economic analysis of dose dense weekly paclitaxel plus carboplatin versus every-3-week paclitaxel plus carboplatin in the treatment of advanced ovarian cancer

Gynecologic Oncology

Volumn 124, Issue 2, 2012, Pages 199-204

  Dalton, Heather J ^a   Yu, Xinhua ^b   Hu, Lilian ^d   Kapp, Daniel S ^c   Benjamin, Ivor ^a   Monk, Bradley J ^a   Chan, John K ^d  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MEMPHIS   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chemotherapy; Economic analysis; Ovary

Indexed keywords

CARBOPLATIN; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; BLOOD TRANSFUSION; BODY WEIGHT; CANCER CHEMOTHERAPY; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DOSAGE SCHEDULE COMPARISON; DRUG COST; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MEDICARE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVARY CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REIMBURSEMENT; SURVIVAL TIME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; COST-BENEFIT ANALYSIS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; FEMALE; HUMANS; MARKOV CHAINS; MIDDLE AGED; MODELS, ECONOMIC; OVARIAN NEOPLASMS; PACLITAXEL; PROPORTIONAL HAZARDS MODELS;

EID: 84856018056     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2011.09.028     Document Type: Article

References (30)

1. A. Jemal, R. Siegel, J. Xu, and E. Ward Cancer statistics, 2010 CA Cancer J Clin 60 2010 277 300
2. C.G. Milross, K.A. Mason, N.R. Hunter, W.K. Chung, L.J. Peters, and L. Milas Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel J Natl Cancer Inst 88 1996 1308 1314 (Pubitemid 26301619)
3. D. Belotti, V. Vergani, T. Drudis, P. Borsotti, M.R. Pitelli, and G. Viale The microtubule-affecting drug paclitaxel has antiangiogenic activity Clin Cancer Res 2 1996 1843 1849 (Pubitemid 26384151)
4. D.H. Lau, L. Xue, L.J. Young, P.A. Burke, and A.T. Cheung Paclitaxel (Taxol): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer Cancer Biother Radiopharm 14 1999 31 36 (Pubitemid 29157732)
5. W.F. Symmans, M.D. Volm, R.L. Shapiro, A.B. Perkins, A.Y. Kim, and S. Demaria Paclitaxel-induced apoptosis and mitotic arrest assessed by serial fine-needle aspiration: implications for early prediction of breast cancer response to neoadjuvant treatment Clin Cancer Res 6 2000 4610 4617 (Pubitemid 32110395)
6. G. Griffon-Etienne, Y. Boucher, C. Brekken, H.D. Suit, and R.K. Jain Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications Cancer Res 59 1999 3776 3782 (Pubitemid 29381886)
7. L. Milas, N.R. Hunter, K.A. Mason, C.G. Milross, Y. Saito, and L.J. Peters Role of reoxygenation in induction of enhancement of tumor radioresponse by paclitaxel Cancer Res 55 1995 3564 3568
8. J.A. Sparano, M. Wang, S. Martino, V. Jones, E.A. Perez, and T. Saphner Weekly paclitaxel in the adjuvant treatment of breast cancer N Engl J Med 358 2008 1663 1671 (Pubitemid 351549913)
9. M.C. Green, A.U. Buzdar, T. Smith, N.K. Ibrahim, V. Valero, and M.F. Rosales Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks J Clin Oncol 23 2005 5983 5992
10. A.D. Seidman, D. Berry, C. Cirrincione, L. Harris, H. Muss, and P.K. Marcom Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840 J Clin Oncol 26 2008 1642 1649
11. M. Markman, J. Hall, D. Spitz, S. Weiner, L. Carson, and L. Van Le Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer J Clin Oncol 20 2002 2365 2369 (Pubitemid 34441665)
12. N. Katsumata, M. Yasuda, F. Takahashi, S. Isonishi, T. Jobo, and D. Aoki Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial Lancet 374 2009 1331 1338
13. E.B. Elkin, and P.B. Bach Cancer's next frontier: addressing high and increasing costs JAMA 303 2010 1086 1087
14. National Heart, Lung, and Blood Institute NHLBI FactBook, Fiscal Year 2009 2009 National Institutes of Health Bethesda, MD
15. W. McGuire, A.I. Neugut, S. Arikian, J. Doyle, and C.M. Dezii Analysis of the cost-effectiveness of paclitaxel as alternative combination therapy for advanced ovarian cancer J Clin Oncol 15 1997 640 645 (Pubitemid 27074233)
16. L.M. Elit, A. Gafni, and M.N. Levine Economic and policy implications of adopting paclitaxel as first-line therapy for advanced ovarian cancer: an Ontario perspective J Clin Oncol 15 1997 632 639 (Pubitemid 27074232)
17. K. Berger, T. Fischer, and T.D. Szucs Cost-effectiveness analysis of paclitaxel and cisplatin versus cyclophosphamide and cisplatin as first-line therapy in advanced ovarian cancer. A European perspective Eur J Cancer 34 1998 1894 1901 (Pubitemid 28535438)
18. R.E. Bristow, A. Santillan, R. Salani, T.P. Diaz-Montes, R.L. Giuntoli II, and B.C. Meisner Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: a cost-effectiveness analysis Gynecol Oncol 106 2007 476 481 (Pubitemid 47302480)
19. L.J. Havrilesky, A.A. Secord, K.M. Darcy, D.K. Armstrong, and S. Kulasingam Cost effectiveness of intraperitoneal compared with intravenous chemotherapy for women with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study J Clin Oncol 26 2008 4144 4150
20. R.P. Rocconi, A.S. Case, J.M. Straughn Jr. , J.M. Estes, and E.E. Partridge Role of chemotherapy for patients with recurrent platinum-resistant advanced epithelial ovarian cancer: a cost-effectiveness analysis Cancer 107 2006 536 543 (Pubitemid 44107214)
21. D.E. Cohn, K.H. Kim, K.E. Resnick, D.M. O'Malley, and J.M. Straughn Jr. At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis J Clin Oncol 29 2011 1247 1251
22. W.P. McGuire, W.J. Hoskins, M.F. Brady, P.R. Kucera, E.E. Partridge, and K.Y. Look Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer N Engl J Med 334 1996 1 6 (Pubitemid 26012496)
23. R.F. Ozols, B.N. Bundy, B.E. Greer, J.M. Fowler, D. Clarke-Pearson, and R.A. Burger Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study J Clin Oncol 21 2003 3194 3200 (Pubitemid 46606249)
24. N. Maniadakis, U. Dafni, V. Fragoulakis, I. Grimani, E. Galani, and A. Fragkoulidi Economic evaluation of taxane-based first-line chemotherapy in the treatment of patients with metastatic breast cancer in Greece: an analysis alongside a multicenter, randomized phase III clinical trial Ann Oncol 20 2009 278 285
25. A. Benedict, D.A. Cameron, H. Corson, and S.E. Jones An economic evaluation of docetaxel and paclitaxel regimens in metastatic breast cancer in the UK Pharmacoeconomics 27 2009 847 859
26. C. Frias, J. Cortes, M.A. Segui, I. Oyaguez, and M.A. Casado Cost-effectiveness analyses of docetaxel versus paclitaxel once weekly in patients with metastatic breast cancer in progression following anthracycline chemotherapy, in Spain Clin Transl Oncol 12 2010 692 700
27. R.A. Hirth, M.E. Chernew, E. Miller, A.M. Fendrick, and W.G. Weissert Willingness to pay for a quality-adjusted life year: in search of a standard Med Decis Making 20 2000 332 342 (Pubitemid 30479101)
28. C.P. Lee, G.M. Chertow, and S.A. Zenios An empiric estimate of the value of life: updating the renal dialysis cost-effectiveness standard Value Health 12 2009 80 87
29. American Cancer Society Cancer Facts & Figures 2009 2009 Atlanta
30. W.P. McGuire, W.J. Hoskins, M.F. Brady, P.R. Kucera, E.E. Partridge, and K.Y. Look Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group) Semin Oncol 23 1996 40 47 (Pubitemid 26391379)